These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 14072937)

  • 1. ANTINUCLEAR AND PRECIPITATING AUTOANTIBODIES IN PROGRESSIVE SYSTEMIC SCLEROSIS.
    BECK JS; ANDERSON JR; GRAY KG; ROWELL NR
    Lancet; 1963 Dec; 2(7319):1188-90. PubMed ID: 14072937
    [No Abstract]   [Full Text] [Related]  

  • 2. [Comparative studies of the diagnostic usefulness of the intracutaneous leukocyte test and antinuclear factors in chronic lupus erythematosus].
    Sönnichsen N
    Z Haut Geschlechtskr; 1967 Jun; 42(12):413-6. PubMed ID: 4872830
    [No Abstract]   [Full Text] [Related]  

  • 3. [Determination of antinuclear autoantibodies in progressive systemic sclerosis and its clinical significance].
    Jiang M; Wang HZ; Yuan X
    Zhonghua Nei Ke Za Zhi; 1988 Feb; 27(2):112-4, 136. PubMed ID: 3053068
    [No Abstract]   [Full Text] [Related]  

  • 4. Antinuclear antibodies in progressive systemic sclerosis.
    Riboldi P; Asero R; Origgi L; Crespi S; Meroni PL; Sguotti C; Sabbadini MG
    Clin Exp Rheumatol; 1985; 3(3):205-11. PubMed ID: 3902296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis.
    Gupta RC; Seibold JR; Krishnan MR; Steigerwald JC
    Clin Exp Immunol; 1984 Oct; 58(1):68-76. PubMed ID: 6434213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III.
    Hirakata M; Okano Y; Pati U; Suwa A; Medsger TA; Hardin JA; Craft J
    J Clin Invest; 1993 Jun; 91(6):2665-72. PubMed ID: 8390487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Diagnostic significance of scleroderma and myositis-associated autoantibodies].
    Genth E; Mierau R
    Z Rheumatol; 1995; 54(1):39-49. PubMed ID: 7725809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antinuclear autoantibodies in systemic diseases].
    Butov IuS
    Vestn Dermatol Venerol; 1980 Nov; (11):17-22. PubMed ID: 7003977
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical subsets of scleroderma: relevance of fluorescent and precipitating antinuclear antibodies.
    Cassani F; Tosti A; Bianchi FB; Fusconi M; Selleri L; Baffoni L; Veronesi S; Volta U; Lenzi M; Pisi E
    Clin Exp Rheumatol; 1987; 5(1):23-8. PubMed ID: 3109797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antinuclear antibodies in mesenchymal scleroderma and progressive systemic sclerosis (author's transl)].
    Sugiura M; Hashimoto T; Kurihara S; Nishikawa T; Hatano H
    Nihon Hifuka Gakkai Zasshi; 1980 Sep; 90(10):935-7. PubMed ID: 7012401
    [No Abstract]   [Full Text] [Related]  

  • 11. [Progressive systemic sclerosis-scleroderma. Experience with 67 cases].
    GONZALEZ A
    Rev Med Chil; 1959 Jul; 87():498-516. PubMed ID: 13850974
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical significance of anti-nucleolar antibodies detected by immunoprecipitation method in patients with systemic sclerosis].
    Kuwana M; Mimori T; Hama N; Kaburaki J; Okano T; Tojo T
    Ryumachi; 1992 Feb; 32(1):39-46. PubMed ID: 1604415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dermatologic and visceral aspects of diffuse and progressive scleroderma (acro-sclerosis) (3 cases)].
    BECHELLI LM; FONSECA LC; PIMENTA WP
    An Bras Derm Sifilogr; 1956 Mar; 31(1):17-45. PubMed ID: 13362913
    [No Abstract]   [Full Text] [Related]  

  • 14. RNA polymerase III autoantibodies may indicate renal and more severe skin involvement in systemic sclerosis.
    Terras S; Hartenstein H; Höxtermann S; Gambichler T; Kreuter A
    Int J Dermatol; 2016 Aug; 55(8):882-5. PubMed ID: 26499848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoantibodies against nuclear, nucleolar, and mitochondrial antigens in systemic sclerosis (scleroderma).
    Reimer G
    Rheum Dis Clin North Am; 1990 Feb; 16(1):169-83. PubMed ID: 2406806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and clinical profiles of 'autoantibody-negative' systemic sclerosis subjects.
    Hudson M; Satoh M; Chan JY; Tatibouet S; Mehra S; Baron M; Fritzler M;
    Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-127-32. PubMed ID: 24144389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis.
    Kuwana M; Kaburaki J; Mimori T; Tojo T; Homma M
    J Clin Invest; 1993 Apr; 91(4):1399-404. PubMed ID: 8473491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical vignette: paraneoplastic diffuse systemic sclerosis.
    Nowak K; Wright G
    Rheumatology (Oxford); 2022 Oct; 61(10):e323. PubMed ID: 35176133
    [No Abstract]   [Full Text] [Related]  

  • 19. Progressive systemic sclerosis (scleroderma).
    BEIGELMAN PM; GOLDNER F; BAYLES TB
    N Engl J Med; 1953 Jul; 249(2):45-58. PubMed ID: 13063682
    [No Abstract]   [Full Text] [Related]  

  • 20. Autoantibody profile in systemic sclerosis.
    Behmanesh F; Amin R; Khajedaluee M; Fritzler MJ
    Acta Med Iran; 2010; 48(1):12-20. PubMed ID: 21137663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.